Description
Pre-made Lentivirus express the CAR construct of “3xFLAG-anti-BCMA-ScFV (VL-VH)-CD8 hinge-CD28-CD3ζ”. It contains the GFP-Puromycin dual marker, allowing the selection of the transduced cells via antibiotic killing, or via GFP positive cell sorting.
This CAR construct, contains the N-term 3xFLAG tagged “BCMA-scFv [VH-(G4S)x4-VL]” recognition domain, linked to CD28 stimulatory domain, expressed under the enhance EF1a promoter. The lentivector’s core structure is represented by the scheme below.
BCMA is expressed on the surface of plasma cells, particularly mature B cells, and plays a role in B cell development. BCMA is a target in CAR-T therapy for multiple myeloma. This CAR’s anti-BCMA use the hybrid clone 125 / 171 (Reference).
see details in Product Manual.
CD28, a transmembrane protein on T cells, provides co-stimulatory signals for T cell activation and proliferation. CD28 costimulatory domains in CARs enhance anti-malignancy efficacy, making it a common choice in CAR design.
CD3ζ (T-cell receptor zeta) is expressed by T cells and NK cells. It together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. CD3-zeta is the most commonly used activation component of CARs. It transmits an activation signal to the T cell after the antigen is bound. It can be coupled with additional co-stimulatory signaling for the complete activation.
Negative Controls: To validate the specificity of the targeted CAR-T killing, you can use the negative control CAR lentivirus: the CAR-ctr8 that has the same lentivector backbone but removed the recognition domain.
Amount: 200 ul/vial at titer of 1×108 IFU/ml, concentrated lentivirus provided in PBS solution, premixed with 10x polybrene (60ug/ml), premade, ready to ship in dry-ice package.
CAT#: LVP1652
